Edaravone in the Treatment of Optic Neuritis

First Affiliated Hospital of Guangxi Medical University

Status: Enrolling

Conditions: Optic Neuritis

Treatments: Drug: Edaravone

Study type: Interventional

Funder types: Other

Identifiers

NCT05540262

GXEDAON1.0

Details and patient eligibility

About

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
2. Patients with a first episode of optic neuritis in either eye
3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone

Exclusion criteria

1. Myopia over 6 diopters
2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Edaravone

Experimental group

Treatment:

Drug: Edaravone